Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Azacitidine in MDS and AML
NCT02775903Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2016
- Primary completion
- Dec 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of durvalumab in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Overall Response Rate up to 34 months. Started Jun 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
myelodysplastic syndromes (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02775903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02775903.